Life-changing and potentially life-saving
Therapies in Leukemia and Cancer

We are a privately-owned biotech pioneering late-stage therapy for hematology/oncology and chronic inflammation. Both our clinical-stage  biologic agents have been and are being clinically tested and our lead candidate, Lenzilumab (LENZ), is completing a Phase 2/3 trial which is >90% enrolled as a therapy for patients who have treatment-naive Chronic MyeloMonocytic Leukemia (CMML).

LENZ is demonstrating encouraging data in a range of myeloid disorders. 
Recent epidemiology and independent patient registries from leading centers and governments in 5 different countries lead to an estimated 60,000 patients in the US and European major 5 countries.

The clinical response rate to LENZ on top of Standard of Care of >80% (using well-accepted clinical measures) is more than 4 times the published standard of care response when used alone and LENZ is demonstrating excellent safety and tolerability in this condition, as it has in all the other conditions in which it has previously studies. More than 700 patients have received LENZ in multiple studies and conditions and in many different countries.

Additional encouraging data with LENZ has been presented in other serious, life-threatening myeloid conditions, such as AML and in MDS, effectively doubling the patient population to well over 100,000 people.

In addition, LENZ has demonstrated promising data in clinical studies as a companion therapy to CAR-T to minimize or eliminate serious and potentially life-threatening side-effects associated with the CAR-T therapy.
A Phase 3 protocol for potential registration for LENZ in this use has been signed off by FDA.